BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary

BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary

Moby Intelligence

Tue, August 11, 2026 at 8:25 PM GMT+3 3 min read

Strategic Shift and Operational Performance

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Secured the first-ever CDMO manufacturing and supply agreement for a rare premium fragrance, significantly ahead of the previously outlined schedule.

• Transitioning strategy from proving the breadth of Botanical Synthesis applications to selectively converting high-value opportunities into recurring manufacturing revenue and royalties.

• Reallocated capital and management focus from the direct-to-consumer (D2C) business toward manufacturing capacity build-out and the growing CDMO division.

• Attributed the D2C revenue guidance reduction to deliberate spending discipline in response to double-digit media inflation on platforms like Meta.

• Implemented a pricing increase of up to 20% for new subscription customers starting with their second order to improve unit economics without material impact on retention.

• Leveraging existing developed molecules (olive, pomegranate, blueberry) as CDMO assets to accelerate time-to-market for strategic partners.

• Utilizing non-dilutive funding from the Israel Innovation Authority to integrate AI and machine learning into biological development workflows.

Outlook and Strategic Roadmap

• Targeting consolidated EBITDA breakeven in 2027 while managing cash to avoid future equity-based funding rounds.

• Projecting the new fragrance agreement to generate $20 million to $30 million in revenue during the 2027-2028 time frame, with limited production starting in H1 2027.

• Anticipating a significant reduction in full-year CDMO EBITDA loss to a range of $1.5 million to $2.5 million due to high-value project prioritization.

• Planning the launch of single-dose VINIA Daily Chews in September 2026 to drive conversion among younger audiences and deepen customer retention.

• Developing a long-term licensing model for high-volume products like sweeteners, where partners build their own facilities while BioHarvest collects royalties.

Risk Factors and Structural Adjustments

• Revised total 2026 revenue guidance downward to $37 million to $40 million from the previous $42 million to $48 million range.

• Acknowledged significant media inflation as a headwind for the D2C business, necessitating a shift in brand messaging and acquisition strategy.

• The fragrance contract includes a 20% ownership position in the business profit, though specific royalty percentages remain under negotiation.

• Capacity expansion for 2028 will be staggered and funded through generated cash rather than upfront heavy capital expenditure.

Q&A Session Summary

Fragrance production timeline and revenue recognition

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

• Management confirmed they will bypass the traditional Stage 3 scale-up by starting commercial production in smaller bioreactors in H1 2027.

• Revenue from product sales will be recognized starting in the first half of 2027 rather than waiting for the completion of the larger facility in 2028.

Resource allocation and CDMO revenue guidance tightening

• The tightening of the CDMO revenue range reflects a decision to focus on high-value projects like the fragrance program rather than chasing a high volume of smaller opportunities.

• This focus is intended to accelerate the path to manufacturing and sustainable profitability.

Tate & Lyle partnership expansion and facility funding

• BioHarvest is pursuing a model where large-volume partners like Tate & Lyle build their own facilities, with BioHarvest providing technology transfer in exchange for royalties.

• This strategy is designed to minimize BioHarvest's capital expenditure and cash consumption for high-volume nutritional products.

Exclusivity and long-term potential of fragrance contract

• BioHarvest is currently the exclusive manufacturer for this specific fragrance raw material and expects the relationship to continue multi-year.

• Management reiterated a projection of $180 million in revenue from this fragrance molecule over its first five years of manufacturing.